Everything below concerns heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
R6890, sometimes known as spirochlorphine, is an orphine opioid analgesic and a member of the spiropiperidine family of agents. The first known mention of this compound was in 1977. Other examples of agents from this class are Ro64-6198 and Ro65-6570. Brorphine also has a similar structure. It has been sold as a designer drug, and was proposed for placement on the Schedule 1 list in the USA on 1 July 2026. A precursor chemical used in the synthesis of R6890 is 1-phenyl-1,3,8-triazaspiro(4,5)decan-4-one (also known as spirodecanone), which is used in the synthesis of other drugs including spirilene, fluspirilene, spiramide, spiperone, RP-23618, spiroxatrine, L008716 and R5260.
The core culture of Brazil is derived from Portuguese culture, due to its strong colonial ties with the Portuguese Empire. Among other influences, the Portuguese introduced the Portuguese language, Roman Catholicism and colonial architectural styles. Brazilian culture was also strongly influenced by African, indigenous and non-Portuguese European cultures and traditions. Some aspects of Brazilian culture were shaped by the contributions of successive waves of immigrants who arrived in large numbers in the south and southeast of Brazil during the 19th and 20th centuries, including Italians, Germans and other Europeans as well as Japanese, Jewish and Arab communities. The indigenous Amerindians influenced Brazil's language and cuisine; and the Africans influenced language, cuisine, music, dance and religion. Brazilian art has developed since the 16th century into different styles that range from Baroque (the dominant style in Brazil until the early 19th century) to Romanticism, Modernism, Expressionism, Cubism, Surrealism and Abstractionism. Brazilian cinema dates back to the birth of the medium in the late 19th century and has gained a new level of international acclaim since the 1960s. Brazilian culture has long enjoyed periodic global influence and interest, often described as the phenomenon of "Brazilianness" (brasilidade)—a unique blend of music, dance, cinema, sport and other cultural elements that attract emulation, admiration, and commentary.
the quality of school lunches the emphasis of schools on physical activity access to vending machines and fast-food restaurants prevalence of and access to parks, bike paths, and sidewalks government subsidies for corn oil and sugar advertising of fast-food restaurants and candy prices of healthy and unhealthy foods access to fresh, healthy, and affordable food
For adult men, as oral doses were increased from 0.5 mg to 1.1 mg, there was a modest linear increase in urinary riboflavin, reaching 100 micrograms for a subsequent 24-hour urine collection. Beyond a load dose of 1.1 mg, urinary excretion increased rapidly, so that with a dose of 2.5 mg, urinary output was 800 micrograms for a 24-hour urine collection.
They cited concerns over deviations from standard acquisition processes and a dome subscription model that could "give Musk undue influence over national security." Another key conflict of interest involves four-star general Terrence J. O'Shaughnessy, former head of U.S. homeland missile defense, who now reports directly to Musk at SpaceX. Michael D. Griffin, founder of the Space Development Agency behind the Golden Dome, has also faced scrutiny. After traveling to Russia with a young Musk in 2001 to study ICBMs, Griffin steered $2 billion in NASA contracts to Musk's newfound space company. SpaceX has since secured missile-tracking satellite contracts through Griffin's SDA as part of its Starshield program. Griffin also serves as an advisor to Castelion, a startup founded by former SpaceX executives that seeks to mass-produce hypersonic weapons. General Michael A. Guetlein of the U.S. Space Force, was nominated to run the program in June 2025, was confirmed by the Senate the following month, and assumed the position on July 21, 2025. Dr. Douglas Matty was named to head the project in January 2026. Republicans included $25 billion for the Golden Dome in their 2025 reconciliation spending bill. The fiscal 2026 defense appropriations bill, passed by Congress on February 3, 2026, included $13.4 billion for space and missile defense systems for the Golden Dome. As of December 2025, the U.S.
Sources: en.wikipedia.org
== RCM Beynon Prize == To mark the 80th birthday of John H. Beynon, the founding Editor of RCM, in 2004 an annual award was established in his honour by the publishers. The award is made on the recommendation of an ad hoc Sub-committee of the editorial board of RCM.
They also played "Rooster" with Comes with the Fall vocalist William DuVall and Ann Wilson. The band followed the concert with a short United States club tour named "Finish What We Started", several festival dates in Europe, and a brief tour in Japan. Duff McKagan again joined the band for the reunion tour, playing rhythm guitar on selected songs. During the tour, the band played a 5-minute video tribute to Staley during the changeover from the electric to acoustic set. To coincide with the band's reunion, Sony Music released the long-delayed third Alice in Chains compilation, The Essential Alice in Chains, a double album that includes 28 songs. Jerry Cantrell met William DuVall in Los Angeles in 2000 through a mutual acquaintance who introduced Cantrell to Comes with the Fall's first album. Cantrell started hanging out with the band and occasionally joined them onstage. Between 2001 and 2002, Comes with the Fall was both the opening act on Cantrell's tour for his second solo album, Degradation Trip, and also his backing band, with DuVall singing Staley's parts at the concerts. DuVall joined Alice in Chains as lead singer during the band's reunion concerts in 2006, and made his first public performance with the band at VH1's Decades Rock Live! concert. According to Cantrell, it only took one audition for DuVall to get the gig. For his first rehearsal with the band, DuVall sang "Love, Hate, Love".
==== Freeze-drying ==== This method is the most expensive out of all dehydration methods but provides the advantage of long stable shelf life at room temperature and an excellent retention of soluble nutrients (nitrogen protein and other solids). The product undergoes quick freeze at 10 °C (50 °F) and is then dried at a moderate temperature inside a strong vacuum. Due to the expensive nature of the equipment, the final product price is higher than tempeh preserved through other methods.
Digital Audio Broadcasting (DAB) debuted in some countries in 1998. It transmits audio as a digital signal rather than an analog signal as AM and FM do. DAB has the potential to provide higher quality sound than FM (although many stations do not choose to transmit at such high quality), has greater immunity to radio noise and interference, makes better use of scarce radio spectrum bandwidth and provides advanced user features such as electronic program guides. Its disadvantage is that it is incompatible with previous radios so that a new DAB receiver must be purchased. Several nations have set dates to switch off analog FM networks in favor of DAB / DAB+, notably Norway in 2017 and Switzerland in 2024. A single DAB station transmits a 1,500 kHz bandwidth signal that carries from 9–12 channels of digital audio modulated by OFDM from which the listener can choose. Broadcasters can transmit a channel at a range of different bit rates, so different channels can have different audio quality. In different countries DAB stations broadcast in either Band III (174–240 MHz) or L band (1.452–1.492 GHz) in the UHF range, so like FM reception is limited by the visual horizon to about 40 miles (64 km). HD Radio is an alternative digital radio standard widely implemented in North America. An in-band on-channel technology, HD Radio broadcasts a digital signal in a subcarrier of a station's analog FM or AM signal. Stations are able to multicast more than one audio signal in the subcarrier, supporting the transmission of multiple audio services at varying bitrates.
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.